Ask AI
ProCE Banner Activity

Nursing Challenges in Managing and Coordinating Care for Patients Experiencing Long-term Toxicities Related to CAR T-Cell Therapies

Clinical Thought

In this commentary, experts discuss clinical evidence and practical considerations for optimizing nursing care of patients with relapsed/refractory multiple myeloma receiving bispecific antibody therapy. The commentary highlights efficacy findings from the MajesTEC-3 and MajesTEC-1 trials and examines the recognition and management of treatment-related adverse events, including CRS, ICANS, and infections. Strategies for infection prevention, including IVIG prophylaxis, and supportive care approaches for managing talquetamab-associated toxicities are addressed. The experts also emphasize patient and caregiver education, early symptom recognition, and coordination between academic and community oncology settings to support safe treatment administration, timely intervention, and preservation of patients' quality of life.

Released: October 26, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity has been designed to meet the educational needs of community oncology nurses, nurse practitioners, and other healthcare professionals caring for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with multiple myeloma

  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma

Financial Disclosures

Primary Author

Charise Gleason, MSN, NP-C, AOCNP, has no relevant financial relationships to disclose.

Tiffany Richards, PhD, ANP-BC, AOCNP: consultant/advisor/speaker: Bristol Myers Squibb, Pfizer, Regeneron, Sanofi.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.